NeuroPace NPCE 深 滬
等待開盤 09-23 09:30:00 美东时间
14.71
+0.170
+1.17%
華盛通- 最 高14.9349
- 今 開14.75
- 成交量 16.05万股
- 最 低 14.54
- 昨 收 14.54
- 總市值 5.05亿
- 52周最高 19.60
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 9.22
- 委 比 1.47%
- 總股本 3432.43万
- 歷史最高 27.38
- 量 比 1.28
- 振 幅 2.72%
- 歷史最低 1.22
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18
Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.
09-18 18:38
NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est
NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
08-12 04:08
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22
Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Price Target of $22.
07-23 18:13
NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting
--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations----NeuroPace to engage neurosurgeon community through
05-29 20:13
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20
HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $19 to $20.
05-16 01:35
Neuropace shares are trading lower. The company reported Q1 financial results.
Neuropace shares are trading lower. The company reported Q1 financial results.
05-13 21:19
NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript
NeuroPace (NASDAQ:NPCE) released first-quarter financial results and hosted an ...
05-13 05:38
